Viibryd is a prescription medication classified as a serotonin modulator used to treat major depressive disorder. It contains the active ingredient vilazodone which functions by selectively inhibiting the serotonin transporter to increase synaptic serotonin concentrations. In addition it acts as a partial agonist at the 5-ht1a receptor which helps modulate serotonergic neurotransmission and may enhance emotional regulation. These combined actions contribute to the alleviation of depressive symptoms such as low mood and anhedonia. The medication influences neural circuits involved in mood control by supporting sustained serotonin activity across the cortex and limbic structures. Physiologically this leads to improved mood stability and reduced anxiety-related responses in many patients. By enhancing serotonergic signaling Viibryd helps restore balance to mood-related brain functions and promotes a more positive affective state. The overall therapeutic effect results from the drug's ability to increase serotonin availability while simultaneously stimulating 5-ht1a receptors to fine-tune neural communication.

Viibryd is an antidepressant medication that is prescribed to treat major depressive disorder. It works by selectively inhibiting the reuptake of serotonin in the brain. This action increases the amount of serotonin available to signal between nerve cells. The elevated serotonin levels help improve mood and reduce symptoms of depression. Viibryd also acts as a partial agonist at certain serotonin receptors which may enhance its therapeutic effects. Partial receptor activation can fine-tune neurotransmission without causing excessive stimulation. The combined inhibition of reuptake and receptor modulation contributes to its antidepressant efficacy. Overall Viibryd's mechanism targets the brain's serotonin system to restore mood balance.

Nausea is one of the most frequently reported side effects of the medication. Some users experience vomiting or diarrhea, which can lead to dehydration if not managed. Headaches and dizziness are also common, sometimes accompanied by a feeling of light-headedness. Insomnia or abnormal dreams may occur, disrupting normal sleep patterns. A decrease in appetite and occasional weight loss have been observed in clinical studies. Sexual dysfunction, including reduced libido, has been noted in a small number of patients.

Nausea is frequently reported as one of the most common side effects of Viibryd. Diarrhea also occurs in many patients during treatment. Dizziness and light-headedness may be experienced especially when starting the medication. Sleep disturbances such as insomnia or abnormal dreams are frequently noted. Dry mouth and mild constipation are among the additional adverse reactions observed. Fatigue and occasional sweating are also reported side effects.